Amend Surgical
Overview
Amend Surgical, Inc. is a medical device company specializing in the development of advanced biomaterials for surgical applications, particularly bone grafts focused on orthopedics, spine, and dental surgery. Founded in 2015 and based in Alachua, Florida, the company has developed innovative products like NanoFuse®, a combination of bioactive glass and bone graft. Amend Surgical has raised several rounds of funding and collaborates with academic institutions for research and development. It was founded by Robby Lane.
Recent Developments
- 2025: Amend Surgical received additional funding from the Florida Institute and MPWRM Resource Center to accelerate the development and market launch of Amend Tissue Tape™, an innovative product aimed at providing better wound care solutions.
- 2024: The company was awarded a significant product development grant for its suture-less nerve repair device, enhancing its regenerative medicine portfolio.
- 2023: Amend Surgical entered into a partnership with the Wyss Institute to license Tough Gel Technology. This collaboration aims to develop biocompatible adhesives for oral surgery applications, potentially replacing sutures and improving patient comfort during recovery.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2015 |
| Headquarters | Alachua, Florida, USA |
| Founders | Robby Lane |
| Revenue | Not publicly available |
| Profits | Not publicly available |
| Key Investors | Florida Institute, MPWRM |
| Industry | Medical Devices |
| Number of Employees | 2-10 |
Early History
Amend Surgical was established in 2015 with the goal of pioneering advancements in biomaterials used for bone repair and regenerative medicine. The company initially focused on the development of NanoFuse®, a cutting-edge bone graft technology combining bioactive glass with a demineralized delayered bone. This innovation aimed to enhance the healing and regenerative capabilities of bone grafts, garnering interest from both the medical community and investors.
Company Profile and Achievements
Amend Surgical’s journey began with a strong focus on developing products that improve surgical outcomes and patient recovery times. The company's flagship product, NanoFuse®, set the standard for their future innovations:
- NanoFuse®: Addresses critical gaps in bone graft technology by providing bioactive and osteoinductive properties that promote bone regeneration.
- In 2017, Amend Surgical secured a pivotal agreement with UFRF for exclusive rights to biomimetic bone patents, enhancing their intellectual property portfolio.
- By 2020, in collaboration with the Wyss Institute, they licensed the Tough Gel technology to innovate oral surgery adhesive solutions, which demonstrated significant potential to transform dental procedures.
Current Operations and Market Position
Amend Surgical continues to leverage its proprietary technology to expand its market presence in orthopedic and dental surgery fields. The company’s strategic partnerships and consistent innovation have positioned it as a forward-thinking player in medical technology. Its focus on developing adhesive technologies for surgical applications is expected to enhance its reputation for cutting-edge products.
Conclusion
Amend Surgical, Inc. stands out in the medical device industry for its pioneering efforts in bone regeneration and wound care technologies. With innovations like the NanoFuse® and new ventures into biocompatible adhesives, Amend Surgical continues to push the boundaries of what’s possible in surgical healing and recovery. As the company moves forward, it is likely to explore further collaborations and new product innovations that could expand its footprint and impact in the field of regenerative medicine.